Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 87.5% in September

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 100,300 shares, a growth of 87.5% from the August 31st total of 53,500 shares. Based on an average daily trading volume, of 134,500 shares, the days-to-cover ratio is presently 0.7 days. Based on an average daily trading volume, of 134,500 shares, the days-to-cover ratio is presently 0.7 days.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ALPMY shares. Sanford C. Bernstein cut Astellas Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 2nd. Zacks Research raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 9th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy”.

Astellas Pharma Price Performance

Shares of OTCMKTS:ALPMY opened at $11.02 on Friday. Astellas Pharma has a 1-year low of $8.37 and a 1-year high of $12.45. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.17 and a quick ratio of 0.89. The business has a 50-day moving average price of $11.09 and a two-hundred day moving average price of $10.11.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.26. The firm had revenue of $3.41 billion during the quarter, compared to analysts’ expectations of $3.20 billion. Astellas Pharma had a return on equity of 19.67% and a net margin of 4.34%. On average, equities research analysts expect that Astellas Pharma will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.